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Abstract
Background: Human papillomavirus genotypes 52 and 58 (HPV52/58) are frequently detected in patients with
cervical intraepithelial neoplasia (CIN) and invasive cervical cancer (ICC) in East Asian countries including Japan. As
with other HPV genotypes, HPV52/58 consist of multiple lineages of genetic variants harboring less than 10%
differences between complete genome sequences of the same HPV genotype. However, site variations of
nucleotide and amino acid sequences across the viral whole-genome have not been fully examined for HPV52/58.
The aim of this study was to investigate genetic variations of HPV52/58 prevalent among Japanese women by
analyzing the viral whole-genome sequences.
Methods: The entire genomic region of HPV52/58 was amplified by long-range PCR with total cellular DNA extracted
from cervical exfoliated cells isolated from Japanese patients with CIN or ICC. The amplified DNA was subjected to next
generation sequencing to determine the complete viral genome sequences. Phylogenetic analyses were performed
with the whole-genome sequences to assign variant lineages/sublineages to the HPV52/58 isolates. The variability in
amino acid sequences of viral proteins was assessed by calculating the Shannon entropy scores at individual amino
acid positions of HPV proteins.
Results: Among 52 isolates of HPV52 (CIN1, n = 20; CIN2/3, n = 21; ICC, n = 11), 50 isolates belonged to lineage B
(sublineage B2) and two isolates belonged to lineage A (sublineage A1). Among 48 isolates of HPV58 (CIN1, n = 21;
CIN2/3, n = 19; ICC, n = 8), 47 isolates belonged to lineage A (sublineages A1/A2/A3) and one isolate belonged to
lineage C. Single nucleotide polymorphisms specific for individual variant lineages were determined throughout the
viral genome based on multiple sequence alignments of the Japanese HPV52/58 isolates and reference HPV52/58
genomes. Entropy analyses revealed that the E1 protein was relatively variable among the HPV52 isolates, whereas the
E7, E4, and L2 proteins showed some variations among the HPV58 isolates.
Conclusions: Among the HPV52/58-positive specimens from Japanese women with CIN/ICC, the variant distributions
were strongly biased toward lineage B for HPV52 and lineage A for HPV58 across histological categories. Different
patterns of amino acid variations were observed in HPV52 and HPV58 across the viral whole-genome.
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Background
Human papillomaviruses (HPVs) constitute a large family
of small DNA viruses, having a circular double-stranded
DNA genome of approximately 8000 base pairs [1]. Their
genomes share the same genomic organization, and are
composed of at least eight coding regions (early genes: E1,
E2, E4, E5, E6, and E7; late genes: L1 and L2) and two
non-coding regions, including the long control region
(LCR). So far, more than 200 different genotypes of HPV
have been identified as showing more than 10% differ-
ences of the L1 nucleotide sequence in relation to other
genotypes [2]. At least 13 genotypes (HPV16, 18, 31, 33,
35, 39, 45, 51, 52, 56, 58, 59, and 68) [3], referred to as
“high-risk” HPVs, are recognized as the causative agents
of cervical cancer and many other cancers, including vagi-
nal, vulvar, penile, anal, and oropharyngeal cancers [4].
High-risk HPVs preferentially infect basal epithelial cells
and induce hyper-proliferative lesions that are clinically
manifested as cervical intraepithelial neoplasia grade 1
(CIN1) in the cervix. The majority of such infections are
cleared by the host immune system within a few years,
and only a small proportion persist and progress further
to CIN grade 2 or 3 (CIN2/3). These high-grade lesions
eventually develop into invasive cervical cancer (ICC) by
accumulating host genetic alternations after years of
persistent infection [5].
Among the high-risk HPVs, HPV16 and HPV18 are
the most and second most prevalent genotypes in ICC,
respectively, in total accounting for about 70% of ICC
cases worldwide [6]. Although the high prevalence of
HPV16/18 in ICC is common throughout the world, the
distribution of other high-risk HPVs in the remaining
fraction of ICC shows some region-specific variations
[7]. In particular, in East Asian countries including
China, Taiwan, South Korea and Japan, HPV52 and
HPV58 infections are more prevalent compared to
European, North American and African regions [8, 9]. In
Japan, HPV52 and HPV58 ranked the second and third,
respectively, in CIN2/3 cases, and ranked the third and
fourth in ICC cases, accounting for 8–9% and 3–5% of
ICC, respectively [10, 11].
HPV genomes with less than 10% differences in
their L1 sequences, recognized as intra-type variants,
constitutes an additional level of HPV genetic com-
plexity. Based on complete viral genome sequences,
intra-type variants are phylogenetically classified into
different lineages and sublineages, which are defined
as containing 1.0–10.0% and 0.5–1.0% nucleotide vari-
ations, respectively [12]. As such, HPV52 is classified
into four variant lineages (A, B, C, and D) and seven
sublineages (A1, A2, B1, B2, C1, C2, and D), whereas
HPV58 consists of four variant lineages (A, B, C, and
D) and eight sublineages (A1, A2, A3, B1, B2, C, D1,
and D2) [12].
Many lines of evidence attribute a higher risk of
progression to ICC to some distinct variant lineages
of high-risk HPVs. Intriguingly, recent large-scale
studies revealed that different HPV16 variant subli-
neages were associated with different risks for cer-
vical squamous cell carcinoma or adenocarcinoma
[13–15]. A study investigating the worldwide distri-
bution of HPV52 variants also suggested that lineage
B (in particular sublineage B2) posed a higher risk
for cervical cancer development among the variant
lineages [16]. In a study from Taiwan on HPV52 var-
iants, however, lineage C infection posed a higher
risk for CIN3/ICC compared to lineage B [17]. Re-
garding HPV58 variants and their disease association,
lineage A was suggested to be more closely associ-
ated with persistent infection compared to other line-
ages [18], and subsequent studies reported that
sublineage A1 or A3 might be associated with a risk
for CIN3/ICC [17, 19].
While HPV52/58 infections are common in East
Asia, comprehensive surveys have not been conducted
regarding their variant distributions in Japan. Deter-
mining the complete viral genome sequence is the
most reliable and accurate procedure to assign HPV
variant lineages/sublineages compared with utilizing
only limited sequences in the HPV genome, which
was generally done in previous studies on HPV52/58
variant classification [17, 20–22]. This study thus
aimed to collect the whole-genome sequences of
HPV52/58 from Japanese women with CIN/ICC
through next generation sequencing techniques and
perform in-depth analyses of genetic variations of
these particular HPVs.
Methods
Study samples
Cervical exfoliated cells were collected in ThinPrep
media (Hologic, Bedford, MA) using a cytoblush from
Japanese patients diagnosed with CIN1, CIN2, CIN3 or
ICC at Keio University Hospital and Tsukuba University
Hospital from 2012 to 2016. The total cellular DNA was
extracted from the recovered cells on a MagNA Pure LC
2.0 (Roche Diagnostic, Indianapolis, IN), and subjected
to PCR with PGMY09/11 primers to amplify HPV L1
DNA, followed by reverse blot hybridization for HPV
genotyping, as described previously [23]. Based on the
genotyping results, DNA samples positive for HPV52
(n = 52) or HPV58 (n = 47) were selected for subsequent
analyses of the whole-genome sequences of HPV52/58.
The study protocol was approved by the Ethics Commit-
tees at each hospital and the National Institute of
Infectious Diseases, and written informed consent for
study participation was obtained from each patient.
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Table 1 HPV52/58 genomes obtained in this study
ID Histology HPV type Age Length (bp) Lineage Accession No.
HPV52 #001 CIN1 52 65 7960 B2 LC270024
#002 CIN1 52 50 7960 B2 LC270025
#003 CIN1 52 30 7960 B2 LC270026
#004 CIN1 51/52 31 7960 B2 LC270027
#005 CIN1 52/56 24 7960 B2 LC270028
#006 CIN1 52 47 7960 B2 LC270029
#007 CIN1 33/52/69 31 7960 B2 LC270030
#008 CIN1 45/52/53 31 7960 B2 LC270031
#009 CIN1 16/42/52/53 41 7960 B2 LC270032
#010 CIN1 52 40 7960 B2 LC270033
#011 CIN1 42/52/58 23 7960 B2 LC270034
#012 CIN1 52 64 7960 B2 LC270035
#013 CIN1 35/52 40 7960 B2 LC270036
#014 CIN1 52 48 7960 B2 LC270037
#015 CIN1 52 45 7960 B2 LC270038
#016 CIN1 52/82 24 7982** B2 LC270039
#017 CIN1 45/52 31 7960 B2 LC270040
#018 CIN1 31/52 30 7960 B2 LC270041
#019 CIN1 52 37 7960 B2 LC270042
#020 CIN1 33/52 40 7960 B2 LC270043
#021 CIN2 16/52 31 7960 B2 LC270044
#022 CIN2 52 36 7960 B2 LC270045
#023 CIN2 52 28 7960 B2 LC270046
#024 CIN2 52 41 7960 B2 LC270047
#025 CIN2 52 39 7960 B2 LC270048
#026 CIN2 52 53 7960 B2 LC270049
#027 CIN2 52 30 7960 B2 LC270050
#028 CIN2 52 40 7960 B2 LC270051
#029 CIN2 52/58 40 7960 B2 LC270052
#030 CIN2 52 37 7960 B2 LC270053
#031 CIN2 52 33 7960 B2 LC270054
#032 CIN3 18/52/58 36 7960 B2 LC270055
#033 CIN3 52 42 7960 B2 LC270056
#034 CIN3 52 48 7960 B2 LC270057
#035 CIN3 39/52/82 30 7960 B2 LC270058
#036 CIN3 52 31 7937 A1 LC270059
#037 CIN3 52 37 7960 B2 LC270060
#038 CIN3 52 33 7903* B2 LC270061
#039 CIN3 52 49 7960 B2 LC270062
#040 CIN3 52 36 7937 A1 LC270063
#041 CIN3 52 61 7960 B2 LC270064
#042 ICC (SCC) 52 44 7924* B2 LC270065
#043 ICC (SCC) 33/39/52 54 7921* B2 LC270066
#044 ICC (SCC) 52 70 7960 B2 LC270067
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Table 1 HPV52/58 genomes obtained in this study (Continued)
#045 ICC (SCC) 52 68 7960 B2 LC270068
#046 ICC (Ad) 16/18/52 44 7960 B2 LC270069
#047 ICC (SCC) 52 74 7960 B2 LC270070
#048 ICC (SCC) 16/52 47 7960 B2 LC270071
#049 ICC (SCC) 6/16/52 31 7960 B2 LC270072
#050 ICC (SCC) 52 76 7960 B2 LC270073
#051 ICC (SCC) 52 76 7960 B2 LC270074
#052 ICC (SCC) 52 67 7960 B2 LC270075
HPV58 #053 CIN1 42/58 32 7824 A2 LC270076
#054 CIN1 58 35 7824 A1 LC270077
#055 CIN1 58 43 7824 A1 LC270078
#056 CIN1 58 35 7824 A2 LC270079
#057 CIN1 58 31 7824 A2 LC270080
#058 CIN1 16/58/82 27 7824 A1 LC270081
#059 CIN1 58 36 7824 A2 LC270082
#060 CIN1 58 48 7836 A3 LC270083
#061 CIN1 58 34 7824 A1 LC270084
#062 CIN1 42/52/58 23 7824 A1 LC270085
#063 CIN1 58 54 7814*** A2 LC270086
#064 CIN1 58 31 7824 A2 LC270087
#065 CIN1 58/68 44 7824 A1 LC270088
#066 CIN1 58/68 44 7824 A2 LC270089
#067 CIN1 58 30 7824 A2 LC270090
#068 CIN1 58 39 7824 A1 LC270091
#069 CIN1 58 36 7824 A2 LC270092
#070 CIN1 16/31/52/58/66 33 7836 A3 LC270093
#071 CIN1 58 39 7824 A1 LC270094
#072 CIN1 52/58 34 7824 A2 LC270095
#073 CIN1 58 27 7824 A1 LC270096
#074 CIN2 16/52/58 45 7824 A2 LC270097
#075 CIN2 18/52/58 36 7824 A1 LC270098
#076 CIN2 53/58/84 23 7824 A1 LC270099
#077 CIN2 58 45 7824 A2 LC270100
#078 CIN2 58 32 7824 A1 LC270101
#079 CIN2 58 56 7823 A2 LC270102
#080 CIN2 58 45 7823 A1 LC270103
#081 CIN2 58 38 7824 A2 LC270104
#082 CIN2 58 40 7820 C LC270105
#083 CIN2 58 32 7824 A1 LC270106
#084 CIN2 58 33 7824 A2 LC270107
#085 CIN2 58 40 7824 A2 LC270108
#086 CIN3 58 29 7824 A2 LC270109
#087 CIN3 58 38 7836 A3 LC270110
#088 CIN3 58 35 7824 A2 LC270111
#089 CIN3 58 39 7824 A2 LC270112
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Viral whole-genome amplification and next generation
sequencing
Full-circle PCR or overlapping PCR was performed with
PrimeSTAR® GXL DNA polymerase (Takara, Ohtsu,
Japan) to amplify the whole-genome sequences of
HPV52/58 as described previously [24]. The sequences
of PCR primers were as follows: full-circle PCR for
HPV52: HPV52-1758F (5′-ACA CAT ATG GTA ATA
GAA CCA CCA AAA-3′) and HPV52-1908R (5′-TAT
TGT CAA AGC TAT GCT GTA ATA CTG-3′); over-
lapping PCR for HPV52: HPV52-1758F and HPV52-
5968R (5′-TCC AAG CCT GTA CAG GCC CAC ACC
AAC-3′); HPV52-5673F (5′-GTG TAC CTG CCT CCT
GTA CCT GTC TCT-3′) and HPV52-1908R; full-circle
PCR for HPV58: HPV58-1751F (5′-TAC TAT CAA TTC
CTG AAA CAT GTA TGA-3′) and HPV58-1889R (5′-
AAT CTA TCT ATC CAT TCT GGT GTT G-3′); over-
lapping PCR for HPV58: HPV58-1751F and HPV58-
5846R (5′-GCC TGA TAC CTT GGG AAC TAA TAC
TTT-3′); HPV58-5677F (5′-ACC TGC CTC CTG TGC
CTG TGT CTA AGG-3′) and HPV58-1889R. The ampli-
fied DNA was separated by agarose gel electrophoresis and
purified with the Wizard gel purification kit (Promega,
Madison, WI). The purified DNA was converted to a short-
fragmented DNA library using the Nextera XT DNA sam-
ple prep kit (Illumina, San Diego, CA), followed by size se-
lection with SPRIselect (Beckman Coulter, Brea, CA). The
multiplexed libraries were analyzed on a MiSeq sequencer
(Illumina) with the MiSeq reagent kit v3 (150 cycle). The
complete genome sequences of HPV52/58 were de novo
assembled from the total read sequences using the Virus-
TAP pipeline [25] (https://gph.niid.go.jp/cgi-bin/virustap/
index.cgi). The accuracy of the reconstructed whole-
genome sequences was verified by read mapping with
Burrows-Wheeler Aligner v0.7.12 [26] and subsequent vis-
ual inspection by Integrative Genomics Viewer v2.3.90 [27].
Phylogenetic tree construction
The complete genome sequences of HPV52 (n = 52) or
HPV58 (n = 48) isolates were aligned against each other
using MAFFT v7.309 [28] with default parameters, to-
gether with the complete genome sequences of HPV52/
58 available in GenBank, including HPV52/58 reference
genome sequences that represent all variant lineages/
sublineages (HPV52: A1, X74481; A2, HQ537739; B1,
HQ537740; B2, HQ537743; C1, HQ537744; C2,
HQ537746; D, HQ537748; HPV58: A1, D90400; A2,
HQ537752; A3, HQ537758; B1, HQ537762; B2,
HQ537764; C, HQ537774; D1, HQ537768; D2,
HQ537770), and HPV52/58 genome sequences previ-
ously determined by us from Japanese CIN1 specimens
(HPV52: AB819272, AB819273, AB819274; HPV58:
AB819275, AB819276, AB819277, AB819278) [24]. Max-
imum likelihood trees were constructed using RAxML
HPC v8.2.9 [29], employing 1000 bootstrap replicates.
Phylogenetic trees were visualized in FigTree v1.4.3.
Identification of lineage/sublineage-specific SNPs
All the HPV52/58 genome sequences included in the
phylogenetic analyses were used to search for viral single
nucleotide polymorphisms (SNPs) specific for variant
lineages and sublineages. The multiple sequence align-
ments of the whole-genome sequences of HPV52/58
were sorted according to variant lineage/sublineage and
the number of mismatched bases in order to visually
differentiate lineage/sublineage-specific SNPs.
Entropy analysis
Amino acid variations at individual positions of viral
proteins were calculated on the basis of Shannon’s
equation [30]:
Table 1 HPV52/58 genomes obtained in this study (Continued)
#090 CIN3 58 37 7824 A1 LC270113
#091 CIN3 58 27 7824 A2 LC270114
#092 CIN3 58 34 7824 A1 LC270115
#093 ICC (SCC) 58 77 7824 A2 LC270116
#094 ICC (Ad) 16/53/58 39 7836 A3 LC270117
#095 ICC (SCC) 58 79 7824 A2 LC270118
#096 ICC (SCC) 58 48 7824 A1 LC270119
#097 ICC (SCC) 58 64 7824 A2 LC270120
#098 ICC (SCC) 58 54 7824 A1 LC270121
#099 ICC (SCC) 45/58 36 7824 A2 LC270122
#100 ICC (SCC) 58 49 7836 A3 LC270123
CIN cervical intraepithelial neoplasia, ICC invasive cervical cancer, SCC squamous cell carcinoma, Ad adenocarcinoma. The following sequences were identical:
#001, #022 and #033; #004 and #010; #012 and #027; #007 and #018; #020 and #021; #011, #045, #047, and #048; #066, #067, and #084; #058, #068, #075, and
#078. *, E2/E4 deletion; **, L2 insertion; ***, E1 deletion
Tenjimbayashi et al. Infectious Agents and Cancer  (2017) 12:44 Page 5 of 12
H ið Þ ¼ −P
xi
p xið Þlog2p xið Þ
xi ¼ G;A; I;V;……ð Þ;
where H(i), p(xi), and i indicate the amino acid entropy
score of a given position, the probability of occurrence of a
given amino acid at the position, and the number of posi-
tions, respectively. An H(i) score of zero indicates absolute
conservation, whereas a score of 4.4 indicates complete
randomness. The deduced amino acid sequences of eight
HPV proteins (E6/E7/E1/E2/E4/E5/L2/L1) of the HPV52/
58 isolates were concatenated and aligned with each other
using MAFFT. The entropy calculation was performed on
the multiple sequence alignments using R v2.11.1 (https://
cran.r-project.org) with bio3d package v1.1–6 [31].
Statistical analysis
All statistical analyses were performed using R v3.3.2.
Fisher’s exact test was performed to evaluate a difference
in HPV58 A sublineages distribution across histological
categories. P value <0.05 was regarded as statistically sig-
nificant. The relative risk for progression from CIN1 to
CIN2/3/ICC among HPV58 A sublineages was estimated
by calculating adjusted odds ratio with its 95% confi-
dence interval.
Results
Study subjects
The study subjects consisted of 52 HPV52-positive cases
(CIN1, n = 20; CIN2/3, n = 21; ICC, n = 11), and 47
HPV58-positive cases (CIN1, n = 19; CIN2/3, n = 20;
Fig. 1 Phylogenetic tree based on the analyses of HPV52 whole-genome sequences of 52 isolates and 31 genomes available from GenBank (total
83 sequences). Phylogenetic analyses were conducted using the Maximum likelihood algorithm by RAxML with 1000 bootstrap replicates. The
tree is drawn to scale, with branch lengths measured in the number of substitutions per site. The histological grades of cervical specimens from
which the isolates were recovered are shown with colored ID: blue, CIN1; green, CIN2/3; red, ICC
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ICC, n = 8). The mean age ± standard deviation of the
cases in each histological grade was as follows: for
HPV52: CIN1, 38.6 ± 12.0 years; CIN2/3, 38.6 ± 8.3 years;
ICC, 59.2 ± 15.7 years; for HPV58: CIN1, 35.6 ± 7.4 years;
CIN2/3, 37.1 ± 7.5 years; ICC, 55.8 ± 16.2 years.
Phylogenetic analysis of HPV52/58 whole-genomes
By performing long-range PCR covering viral whole-
genomes followed by next generation sequencing analyses,
a total of 100 complete genome sequences of 52 isolates
of HPV52 and 48 isolates of HPV58 were obtained from
the CIN/ICC cases in Japan (Table 1). The lengths of the
determined genome sequences ranged from 7903 to 7982-
bp for HPV52, and from 7814 to 7836-bp for HPV58.
Nucleotide sequence search for open reading frames
(ORFs) identified some deletions and insertions in the
viral genes of several HPV52/58 isolates when compared
to prototype HPV52/58 genomes (HPV52: X74481;
HPV58: D90400) as follows: E2/E4 deletion in three
HPV52 isolates (#038, #042, and #043), L2 insertion in
one HPV52 isolate (#016), and E1 deletion in one HPV58
isolate (#063). Further, the presence of a premature stop
codon was observed in the E4 ORF in one HPV52 isolate
(#052) and one HPV58 isolate (#098).
Phylogenetic analyses were conducted with the whole-
genome sequences of the HPV52/58 isolates, together
with those of reference HPV52/58 genomes that repre-
sent individual variant lineages/sublineages. As shown in
Fig. 2 Phylogenetic tree based on the analyses of HPV58 whole-genome sequences of 48 isolates and 46 genomes available from GenBank (total
94 sequences). Phylogenetic analyses were conducted using the Maximum likelihood algorithm by RAxML with 1000 bootstrap replicates. The
tree is drawn to scale, with branch lengths measured in the number of substitutions per site. The histological grades of cervical specimens from
which the isolates were recovered are shown with colored ID numbers: blue, CIN1; green, CIN2/3; red, ICC
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Fig. 1, several distinct clusters, including each reference
genome, confirmed the presence of four lineages and
seven sublineages for HPV52. Among the 52 isolates of
HPV52 (CIN1, n = 20; CIN2/3, n = 21; ICC, n = 11), 50
isolates belonged to lineage B (sublineage B2) and two
isolates belonged to lineage A (sublineage A1). As shown
in Fig. 2, the reference genomes of HPV58 consistently
revealed the presence of four lineages and eight subli-
neages. Among the 48 isolates of HPV58 (CIN1, n = 21;
CIN2/3, n = 19; ICC, n = 8), 47 isolates belonged to
lineage A (sublineage A1, n = 18; sublineage A2, n = 24;
sublineage A3, n = 5) and one isolate belonged to lineage
C. Interestingly, one HPV58-positive CIN1 specimen
yielded two distinct genome sequences of HPV58 (#065
and #066), and these were classified into two different
sublineages (A1 and A2), which indicates co-infections
with two closely related sublineages of HPV58 in a single
patient. The presence of these two sublineages was fur-
ther confirmed by cloning and Sanger sequencing of
HPV58 PCR products obtained from the original DNA
sample (data not shown).
Overall, among the Japanese isolates of HPV52/58, the
variant distributions were highly biased toward lineage B
(sublineage B2) for HPV52 and lineage A for HPV58.
The distributions of HPV52/58 variant lineage/subline-
age according to cervical histology status when restricted
to single infection (HPV52: n = 33; HPV58, n = 36) are
shown in Table 2. Any association of specific lineage/
sublineage with a higher risk for CIN2/3 and ICC could
not be assessed for the HPV52 isolates, given the domin-
ance of lineage B2 detection across the CIN/ICC cases.
The distribution of HPV58 sublineages A1/A2/A3 was
almost similar across all histological categories, without
a significant difference related to the severity of cervical
lesions (Fisher’s exact test, P = 0.97). Furthermore, no
significant difference in the relative risk for progression
from CIN1 to CIN2/3/ICC was observed among HPV58
sublineages A1/A2/A3 (Table 2).
Lineage/sublineage-specific SNPs in HPV52/58 genomes
Based on multiple sequence alignments of the complete
genome sequences of all HPV52/58 genomes included in
the phylogenetic analyses above, SNPs discriminating
the variant lineages were extracted from the viral whole-
genome sequences. Considering the high prevalence of
HPV52 lineage B and HPV58 lineage A in Japan, we also
searched for SNPs specific for sublineages of these
lineages. All viral SNPs specific for HPV52/58 variant
lineages/sublineages found in this study are presented in
Fig. 3 and listed in Additional file 1.
For HPV52, as shown in Fig. 3a, many lineage D-
specific SNPs were densely distributed throughout the
whole genome, which reflects the phylogenetic distance
of lineage D from other lineages, as shown in Fig. 1. In
contrast, SNPs specific for lineages A/B/C were sparsely
distributed compared to lineage D, and those specific for
lineages B/C were not found in the E6 region, whereas
the E7 region and LCR contained at least one SNP for
discriminating each HPV52 variant lineage.
For HPV58, as shown in Fig. 3b, while lineage-specific
SNPs for lineage A were dispersed across the viral gen-
ome, lineages B/C/D showed relatively biased distributions
of such SNPs in the whole-genome sequence. In particu-
lar, lineage B had only two diagnostic SNPs in the whole
genome, which were positioned in the E1 region and LCR.
Amino acid variation among the HPV52/58 isolates
The variability in amino acid sequences of the viral pro-
teins among the HPV52/58 isolates was examined for
each genotype by calculating the Shannon entropy
scores. As shown in Fig. 4, the overall levels of amino
acid variation were apparently lower in HPV52 than in
HPV58, which reflects a close relationship among the
HPV52 isolates observed as phylogenetic clusters in
Fig. 1. Intriguingly, variable amino acid positions were
differently distributed across the viral proteins be-
tween the HPV52 and HPV58 isolates. In HPV52, the
E1 protein showed relatively high variations among
the viral proteins, whereas in HPV58, the E7, E4, and
L2 proteins showed higher levels of variation in their
amino acid sequences than other proteins. The amino
acid positions with the top three entropy scores for
each genotype were as follows: HPV52: 423 (Lys or
Gln) in E1, 168 (Asn or Thr) in E1, and 429 (Ile or
Thr) in E1; HPV58: 63 (Asp, Ser, or Gly) in E7, 39
(Trp, Leu, or Ser) in E4, and 41 (Arg or Gly) in E7.
Table 2 Distribution of HPV52/58 variant sublineages according
to cervical histology status
Variant Total CIN1 CIN2 CIN3 ICC Adjusted ORa
(95% CI)
HPV52 A1 2 0 0 2 0 -
A2 0 0 0 0 0 -
B1 0 0 0 0 0 -
B2 31 9 9 6 7 -
C 0 0 0 0 0 -
D 0 0 0 0 0 -
HPV58 A1 13 6 3 2 2 1.0 (reference)
A2 19 7 5 4 3 1.47 (0.35–6.17)
A3 3 1 0 1 1 1.71 (0.12–23.9)
B 0 0 0 0 0 ND
C 1 0 1 0 0 ND
D 0 0 0 0 0 ND
Restricted to cases with HPV52 or HPV58 single infection
OR odds ratio, CI confidence interval, ND not determined
arelative risk for progression from CIN1 to CIN2/3/ICC compared to HPV58
sublineage A1
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Discussion
By employing next generation sequencing analyses, we
are able to report the largest number of complete
genome sequences of HPV52/58 in a single study, and
have demonstrated variant distributions of HPV52/58
among Japanese women. Intriguingly, lineage B for
HPV52 and lineage A for HPV58 were predominantly
detected across the CIN/ICC cases in Japan. Moreover,
three HPV52 and four HPV58 genome sequences previ-
ously determined by us [24] were also included in
HPV52 lineage B and HPV58 lineage A, respectively.
These findings are in good agreement with a general
trend in HPV52/58 variant distributions, suggesting that
HPV52 lineage B and HPV58 lineage A are more preva-
lent in Asia than in Europe, the Americas, and Africa
[16, 32]. Further, a high prevalence of lineage B in
HPV52-positive cervical specimens was reported in
South Korea [33] and Taiwan [17], and the dominance
of lineage A in HPV58-positive specimens was also ob-
served in Taiwan [17], which strongly suggests that such
biased distributions of HPV52/58 variant lineages are
common among East Asian countries.
In previous studies, a comparison of HPV52/58 variant
distributions between different grades of cervical lesions
suggested that specific variant lineages, such as HPV52
lineage B [16] and HPV58 lineage A [18], might pose
higher risks for cervical cancer development. Meanwhile,
because of highly dominant distributions of these HPV52/
58 lineages across the CIN/ICC cases in Japan, we were
unable to assess a differential risk of these lineages for
CIN/ICC progression. Thus, the association of HPV52
lineage B or HPV58 lineage A with cervical cancer devel-
opment requires further verification with larger sample
sizes consisting of mixed distributions of variant lineages.
a
b
Fig. 3 Lineage/sublineage-specific SNPs identified from comparisons of whole-genome sequences of the Japanese HPV52/58 isolates and refer-
ence HPV52/58 genomes. The positions of specific SNPs for HPV52 lineages A/B/C/D and sublineages B1/B2 (a) and for HPV58 lineages A/B/C/D
and sublineages A1/A2/A3 (b) are indicated with colored bars. The genome organization of HPV52/58 is shown below: pE, the early promoter; pL,
the late promoter; LCR, the long control region; polyA (early) and polyA (late), the early and late polyadenylation signals, respectively
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Previous studies described E7 T20I/G63S substitutions
in HPV58 as a high-risk signature for ICC development
[19, 34]. Our phylogenetic analysis demonstrated that all
sublineage A3 genomes carried this pair of substitutions;
20I (632 T) was specific to sublineage A3, whereas 63S
(760A) was not restricted to sublineage A3 but also found
in three lineage B genomes (HQ537761, HQ537762, and
HQ537763). The T20I/G63S substitutions were observed
in five HPV58 isolates in this study, all of which belonged
to sublineage A3, although the small sample size pre-
cluded our risk assessment of this variation.
The genomic sequences of several HPV52/58 isolates
showed some characteristic features, such as deletions in
E2/E4 and E1, and insertion in L2. Intriguingly, all E2/
E4 deletions observed in the HPV52 isolates were in-
frame deletions (36, 39, and 57 nucleotides deletions),
and thus supposed to generate internally deleted E2/E4
proteins, which may have altered biological activities for
viral transcription, replication and segregation [35]. Of
particular interest, these deleted E2/E4 genes were all
recovered from CIN3/ICC samples, supporting a prevail-
ing notion that E2 deletion or inactivation favors cervical
cancer progression, because the E2 protein generally re-
presses the viral early promoter responsible for E6/E7
expression, which is required for oncogenic transform-
ation of cervical epithelial cells [1]. The E1 deletion in
HPV58 and the L2 insertion in HPV52, both observed in
CIN1 samples, were not in-frame, and were positioned
near their N-terminus. These two genetic changes would
be expected to abrogate the functions of the correspond-
ing viral proteins, although the consequence of these
deletions on the viral life-cycle and cervical carcinogen-
esis remains unclear.
By comparing the whole-genome sequences of our
Japanese HPV52/58 isolates with those of reference
HPV52/58 genomes representing all variant lineages/
sublineages, we have presented for the first time a com-
prehensive list of specific SNPs for discriminating their
variant lineages/sublineages. In general, these diagnostic
SNPs are dispersed throughout the viral genome, as was
reported for HPV16 [36] and HPV6 [37]. However, cau-
tions should be exercised because some genomic regions
in HPV52/58 lack such diagnostic SNPs for specific
lineage/sublineage identification, as visualized in Fig. 3.
Although previous variant classification for HPV52/58
mostly depended on partial sequences in E6, E7, E2, L1
or LCR [17, 20–22], the diagnostic SNPs described in
this study will be useful for designing new PCR targets
and primers to correctly assign variant lineages/subli-
neages of HPV52/58 in future epidemiological studies.
Previously, a nucleotide substitution in the L1 region
of HPV52 (6764 T to C compared to the prototype,
a
b
Fig. 4 Amino acid variations in viral proteins among the HPV52/58 isolates from Japanese women. Shannon entropy scores representing
variations at individual amino acid positions of eight HPV proteins (E6/E7/E1/E2/E4/E5/L2/L1) were calculated using the ORF sequences of the 52
isolates of HPV52 (a) and the 48 isolates of HPV58 (b). The concatenated viral proteins are shown below
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X74481) was reported to generate a mismatched base to
the GP6+ primer, one of the consensus primers of GP5
+/6+ PCR to amplify L1 DNA of multiple HPV types
[38]. Among the 52 isolates of HPV52 obtained in this
study, 49 isolates (all sublineage B2) carried this sub-
stitution, whereas three isolates (two sublineage A1
and one sublineage B2) had the prototype nucleotide
in this position. Since this substitution precluded the
detection of HPV52 by GP5+/6+ PCR, leading to
underestimation of HPV52 prevalence [38], other PCR
methods, such as PGMY09/11 PCR, should be
employed for epidemiological surveys on HPV52 in
Japan.
The variability of amino acid residues in viral proteins
reflects the degree of non-synonymous substitution in
the nucleotide sequences of ORFs, and the higher vari-
ation at certain amino acid positions suggests that these
positions are either neutral or under diversifying selec-
tion pressure during viral evolution. From such an evo-
lutionary point of view, the different patterns of amino
acid variations in the viral proteins observed in HPV52
and HPV58 are unexpected because these two viruses
are genetically closely related to each other and posi-
tioned on the same branch of an HPV phylogenetic tree
(Alphapapillomaviruse-9) [39]. We speculate that differ-
ent evolutionary pressures may work on the HPV52/58
genomes, thereby restricting or allowing their genomic
diversity in a different manner. Subtle differences in the
viral life-cycle or virus/host interactions, such as the
host immune response, may exist between these closely
related HPVs.
An important unanswered question is why HPV52/58
infections are so common in Asia compared to other
parts of the world. During the long history of HPV evo-
lution and spread across the globe, these genotypes
might have matched a characteristic property of Asian
people through as-yet-unknown mechanisms of viral
adaptation. Since HPV52/58 infections pose a significant
disease burden of cervical cancer on Asian women, fur-
ther work based on the viral whole-genome sequences,
together with elucidation of the genetic background of
Asian people including human leukocyte antigen poly-
morphism, will be required for a better understanding of
cervical carcinogenesis driven by these Asia-prevalent
HPVs.
Conclusions
Among the HPV52/58-positive specimens from Japanese
women with CIN/ICC, the variant distributions were
strongly biased toward lineage B for HPV52 and lineage
A for HPV58 across histological categories. Different
patterns of amino acid variations were observed in
HPV52 and HPV58 across the viral whole-genome.
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